Skip to main content
Clinical Trials/CTRI/2018/06/014537
CTRI/2018/06/014537
Recruiting
未知

A prospective, observational study to assess the effects of SSRI and SNRI on cognitive function in patients of Major Depressive Disorders (MDD)

Department of Pharmacology IPGMER0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: null- All adult diagnosed patients of MDD as per ICD 10 criteria in remission phase
Sponsor
Department of Pharmacology IPGMER
Status
Recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Observational

Investigators

Sponsor
Department of Pharmacology IPGMER

Eligibility Criteria

Inclusion Criteria

  • 1\)Adult patients (18 years to 50 years) of either gender attending psychiatry OPD at IOP,
  • with a clinical diagnosis of Major Depressive Disorder as per ICD10 criteria.
  • 2\)Subjects of MDD must be in remission phase with a Hamilton Depressive Rating Score (HAM\-D 17\) of \<7\) at enrolment and taking any of the following SSRIs \- fluoxetine, sertraline, escitalopram and/or SNRI like mirtazapine for at least last 6 months. Patients who are additionally on cognitive behavioral therapy (CBT) as part of their treatment shall also be included.
  • 3\)Subjects should have at least 8 years of formal school education in order to undertake the cognitive function tests.
  • 4\)Subjects or their care givers should be willing to give written informed.

Exclusion Criteria

  • 1\)History of post traumatic or Obsessive compulsive Disorder (OCD)
  • 2\)History of schizophrenia, psychosis or bipolar delusional disorder
  • 3\)History of intake of any drugs that are likely to have effect on cognition (anticonvulsants, sedative hypnotics, neuroleptics, opioids)
  • 4\)History of addictions\- alcohol, substance abuse

Outcomes

Primary Outcomes

Not specified

Similar Trials